Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane

The EverExt study

Laura Pizzuti, Paolo Marchetti, Clara Natoli, Teresa Gamucci, Daniele Santini, Angelo Fedele Scinto, Laura Iezzi, Lucia Mentuccia, Loretta D'Onofrio, Andrea Botticelli, Luca Moscetti, Francesca Sperati, Claudio Botti, Francesca Ferranti, Simonetta Buglioni, Giuseppe Sanguineti, Simona Di Filippo, Luigi di Lauro, Domenico Sergi, Teresa Catenaro & 5 others Silverio Tomao, Antonio Giordano, Marcello Maugeri-Saccà, Maddalena Barba, Patrizia Vici

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.

Original languageEnglish
Pages (from-to)10597
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Sep 6 2017

Fingerprint

exemestane
Fasting
Body Mass Index
Breast Neoplasms
Glucose
Survival
Everolimus
Proportional Hazards Models

Keywords

  • Journal Article

Cite this

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane : The EverExt study. / Pizzuti, Laura; Marchetti, Paolo; Natoli, Clara; Gamucci, Teresa; Santini, Daniele; Scinto, Angelo Fedele; Iezzi, Laura; Mentuccia, Lucia; D'Onofrio, Loretta; Botticelli, Andrea; Moscetti, Luca; Sperati, Francesca; Botti, Claudio; Ferranti, Francesca; Buglioni, Simonetta; Sanguineti, Giuseppe; Di Filippo, Simona; di Lauro, Luigi; Sergi, Domenico; Catenaro, Teresa; Tomao, Silverio; Giordano, Antonio; Maugeri-Saccà, Marcello; Barba, Maddalena; Vici, Patrizia.

In: Scientific Reports, Vol. 7, No. 1, 06.09.2017, p. 10597.

Research output: Contribution to journalArticle

Pizzuti, L, Marchetti, P, Natoli, C, Gamucci, T, Santini, D, Scinto, AF, Iezzi, L, Mentuccia, L, D'Onofrio, L, Botticelli, A, Moscetti, L, Sperati, F, Botti, C, Ferranti, F, Buglioni, S, Sanguineti, G, Di Filippo, S, di Lauro, L, Sergi, D, Catenaro, T, Tomao, S, Giordano, A, Maugeri-Saccà, M, Barba, M & Vici, P 2017, 'Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study', Scientific Reports, vol. 7, no. 1, pp. 10597. https://doi.org/10.1038/s41598-017-10061-2
Pizzuti, Laura ; Marchetti, Paolo ; Natoli, Clara ; Gamucci, Teresa ; Santini, Daniele ; Scinto, Angelo Fedele ; Iezzi, Laura ; Mentuccia, Lucia ; D'Onofrio, Loretta ; Botticelli, Andrea ; Moscetti, Luca ; Sperati, Francesca ; Botti, Claudio ; Ferranti, Francesca ; Buglioni, Simonetta ; Sanguineti, Giuseppe ; Di Filippo, Simona ; di Lauro, Luigi ; Sergi, Domenico ; Catenaro, Teresa ; Tomao, Silverio ; Giordano, Antonio ; Maugeri-Saccà, Marcello ; Barba, Maddalena ; Vici, Patrizia. / Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane : The EverExt study. In: Scientific Reports. 2017 ; Vol. 7, No. 1. pp. 10597.
@article{da2945976b1c4a7fb31cd552f70769c9,
title = "Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study",
abstract = "Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.",
keywords = "Journal Article",
author = "Laura Pizzuti and Paolo Marchetti and Clara Natoli and Teresa Gamucci and Daniele Santini and Scinto, {Angelo Fedele} and Laura Iezzi and Lucia Mentuccia and Loretta D'Onofrio and Andrea Botticelli and Luca Moscetti and Francesca Sperati and Claudio Botti and Francesca Ferranti and Simonetta Buglioni and Giuseppe Sanguineti and {Di Filippo}, Simona and {di Lauro}, Luigi and Domenico Sergi and Teresa Catenaro and Silverio Tomao and Antonio Giordano and Marcello Maugeri-Sacc{\`a} and Maddalena Barba and Patrizia Vici",
year = "2017",
month = "9",
day = "6",
doi = "10.1038/s41598-017-10061-2",
language = "English",
volume = "7",
pages = "10597",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane

T2 - The EverExt study

AU - Pizzuti, Laura

AU - Marchetti, Paolo

AU - Natoli, Clara

AU - Gamucci, Teresa

AU - Santini, Daniele

AU - Scinto, Angelo Fedele

AU - Iezzi, Laura

AU - Mentuccia, Lucia

AU - D'Onofrio, Loretta

AU - Botticelli, Andrea

AU - Moscetti, Luca

AU - Sperati, Francesca

AU - Botti, Claudio

AU - Ferranti, Francesca

AU - Buglioni, Simonetta

AU - Sanguineti, Giuseppe

AU - Di Filippo, Simona

AU - di Lauro, Luigi

AU - Sergi, Domenico

AU - Catenaro, Teresa

AU - Tomao, Silverio

AU - Giordano, Antonio

AU - Maugeri-Saccà, Marcello

AU - Barba, Maddalena

AU - Vici, Patrizia

PY - 2017/9/6

Y1 - 2017/9/6

N2 - Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.

AB - Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.

KW - Journal Article

U2 - 10.1038/s41598-017-10061-2

DO - 10.1038/s41598-017-10061-2

M3 - Article

VL - 7

SP - 10597

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -